Literature DB >> 11579459

Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect.

S Auroy1, M F Avril, A Chompret, D Pham, A M Goldstein, G Bianchi-Scarrà, T Frebourg, P Joly, A Spatz, C Rubino, F Demenais, B Bressac-de Paillerets.   

Abstract

Multiple primary cancers are one of the hallmarks of inherited predisposition. Outside the familial context, multiple primary tumors could be related either to germline de novo mutations or to low-penetrance mutations, in predisposing genes. We selected 100 patients who displayed multiple primary melanoma (MPM) without any known melanoma cases recorded within their families and looked for germline mutations in the two melanoma-predisposing genes identified to date, CDKN2A and CDK4 exon 2. Nine patients (9%) had germline mutations in CDKN2A, whereas none carried germline mutations in exon 2 of CDK4. Seven cases displayed a recurrent missense mutation, G101W, already described in more than 20 melanoma-prone families; one case carried a missense mutation never reported to date (P114S), and the last case was a carrier of a 6 bp insertion at nucleotide 57 resulting in a duplication of codons 18 and 19. To ascertain whether the G101W was a mutational hot spot for de novo mutations or a common founder mutation, we genotyped eight microsatellite markers flanking the CDKN2A gene. After allowing for recombination over time, haplotype sharing provided evidence for an original G101W mutation common to 6 out of 7 sporadic MPM cases. Therefore, it can be concluded that de novo germline CDKN2A mutations associated with MPM are rare. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579459     DOI: 10.1002/gcc.1183

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  11 in total

1.  High prevalence of germline CDKN2A mutations in Slovenian cutaneous malignant melanoma families.

Authors:  Marko Hocevar; Magdalena Avbelj; Barbara Perić; Janez Zgajnar; Nikola Besić; Tadej Battelino
Journal:  Croat Med J       Date:  2006-12       Impact factor: 1.351

2.  Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.

Authors:  Miriam Potrony; Joan Anton Puig-Butillé; Paula Aguilera; Celia Badenas; Cristina Carrera; Josep Malvehy; Susana Puig
Journal:  J Am Acad Dermatol       Date:  2014-07-24       Impact factor: 11.527

Review 3.  Update in genetic susceptibility in melanoma.

Authors:  Miriam Potrony; Celia Badenas; Paula Aguilera; Joan Anton Puig-Butille; Cristina Carrera; Josep Malvehy; Susana Puig
Journal:  Ann Transl Med       Date:  2015-09

4.  Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.

Authors:  K Laud; C Marian; M F Avril; M Barrois; A Chompret; A M Goldstein; M A Tucker; P A Clark; G Peters; V Chaudru; F Demenais; A Spatz; M W Smith; G M Lenoir; B Bressac-de Paillerets
Journal:  J Med Genet       Date:  2005-06-03       Impact factor: 6.318

5.  Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3.

Authors:  Juliette Delaunay; Ludovic Martin; Brigitte Bressac-de Paillerets; Gerard Duru; Olivier Ingster; Luc Thomas
Journal:  JAMA Dermatol       Date:  2017-11-01       Impact factor: 10.282

Review 6.  Selection criteria for genetic assessment of patients with familial melanoma.

Authors:  Sancy A Leachman; John Carucci; Wendy Kohlmann; Kimberly C Banks; Maryam M Asgari; Wilma Bergman; Giovanna Bianchi-Scarrà; Teresa Brentnall; Brigitte Bressac-de Paillerets; William Bruno; Clara Curiel-Lewandrowski; Femke A de Snoo; Tadeusz Debniak; Marie-France Demierre; David Elder; Alisa M Goldstein; Jane Grant-Kels; Allan C Halpern; Christian Ingvar; Richard F Kefford; Julie Lang; Rona M MacKie; Graham J Mann; Kurt Mueller; Julia Newton-Bishop; Håkan Olsson; Gloria M Petersen; Susana Puig; Darrell Rigel; Susan M Swetter; Margaret A Tucker; Emanuel Yakobson; John A Zitelli; Hensin Tsao
Journal:  J Am Acad Dermatol       Date:  2009-10       Impact factor: 11.527

Review 7.  An interstitial deletion within 9p21.3 and extending beyond CDKN2A predisposes to melanoma, neural system tumours and possible haematological malignancies.

Authors:  Maria J Baker; Alisa M Goldstein; Patricia L Gordon; Kimberly S Harbaugh; Heath B Mackley; Michael J Glantz; Joseph J Drabick
Journal:  J Med Genet       Date:  2016-01-21       Impact factor: 6.318

8.  BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.

Authors:  Christian Monnerat; Agnès Chompret; Caroline Kannengiesser; Marie-Françoise Avril; Nicolas Janin; Alain Spatz; Jean-Marc Guinebretière; Catalin Marian; Michel Barrois; Françoise Boitier; Gilbert M Lenoir; Brigitte Bressac-de Paillerets
Journal:  Fam Cancer       Date:  2007-07-12       Impact factor: 2.375

9.  Dermoscopy comparative approach for early diagnosis in familial melanoma: influence of MC1R genotype.

Authors:  C Longo; V Barquet; E Hernandez; A A Marghoob; M Potrony; C Carrera; P Aguilera; C Badenas; J Malvehy; S Puig
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-28       Impact factor: 9.228

10.  Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma.

Authors:  N Soufir; J J Lacapere; G Bertrand; E Matichard; R Meziani; D Mirebeau; V Descamps; B Gérard; A Archimbaud; L Ollivaud; F Bouscarat; M Baccard; G Lanternier; P Saïag; C Lebbé; N Basset-Seguin; B Crickx; H Cave; B Grandchamp
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.